Slowing or Delaying Vision Loss in Retinitis Pigmentosa (USH2A gene mutation subtype) → Gene Therapy Can Slow or Stop Progression → Contribution
Are there active clinical trials for USH2A RP?
Method
Search of ClinicalTrials.gov, EU Clinical Trials Register, and published trial summaries for USH2A-related interventions.
Data / Sources
ClinicalTrials.gov database, company pipeline announcements, recent review articles.
Result
Multiple trials ongoing: ProQR (AON/exon skipping), Editas Medicine (CRISPR), Foundation Fighting Blindness supported trials, several stem cell studies. Most are Phase 1-2.
Insight
The field is active and well-funded, but most therapies are still experimental. No treatment has yet reached Phase 3 approval for USH2A-specific RP.
Suggested Next Step
Create a tracker of active trials with expected completion dates. Monitor for interim results.